Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Active Biotech
Deal Size : Undisclosed
Deal Type : Acquisition
Active Biotech Acquires Exclusive Rights to Patents of Tasquinimod in Combination Therapy
Details : Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.
Brand Name : ABR-215050
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Active Biotech
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NICE Recommends All-oral Treatment For Multiple Myeloma
Details : Ninlaro® (ixazomib) is the first and only oral proteasome inhibitor licensed in combination with lenalidomide and dexamethasone for adults with multiple myeloma (MM).
Brand Name : Ninlaro
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 19, 2023
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2021
Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ninlaro (ixazomib) is an oral proteasome inhibitor, small molecule drug candidate which is being evaluated for the treatment of patients with multiple myeloma.
Brand Name : Ninlaro
Molecule Type :
Upfront Cash : Not Applicable
September 09, 2020
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation.
Brand Name : Ninlaro
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2020
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TOURMALINE-MM4, a Phase 3, randomized clinical trial evaluating the effect of single-agent oral NINLARO™ (ixazomib), an oral proteasome inhibitor used as a first-line maintenance therapy in adult patients diagnosed with multiple myeloma.
Brand Name : Ninlaro
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2020
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
Details : The addition of ixazomib to lenalidomide and dexamethasone resulted in an improvement in median progression-free survival of 13.5 months; however, it did not meet the statistical significance.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2020
Lead Product(s) : Ixazomib Citrate,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?